A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.
What the source actually supports
- Evidence stage
- Phase 1, Phase 2
- Study design
- RANDOMIZED · PARALLEL · TREATMENT · DOUBLE
- Evidence population
- Human clinical study registration
- Participants
- 65
- Population
- ALL · 60 Years to 95 Years
- Duration
- 2014-03-03 to 2020-10-02
- Intervention
- Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs); Placebo; Penicillin/Streptomycin-Free Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
- Comparator
- Not reported
- Outcomes measured
- Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs) — One Month post infusion; Change in Frailty as Assessed by CHAMPS Questionnaire — At baseline and 6 month follow-up visit.; Change in Slowing of Mobility as Measured by 4 Meter Gait Speed Test — At baseline and 6 month follow-up visit.; Change in Slowing of Mobility as Measured by SPPB — At baseline and 6 month follow-up visit.; Change in Weight — At baseline and 6 month follow-up visit.; Change in Diminished Hand Grip Strength — At baseline and 6 month follow-up visit.; Change in Exhaustion as Measured by the MFI Questionnaire — At baseline and 6 month follow-up visit.; Change in Quality of Life (QoL) as Measured by the ICECAP Questionnaire — At baseline and 6 month follow-up visit.; Change in Quality of Life (QoL) as Measured by the SF-36 Questionnaire — At baseline and 6 month follow-up visit.; Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Questionnaire — At baseline and 6 month follow-up visit.; Change in Quality of Life (QoL) as Measured by the EQ-5D-3L Overall Health Status Scale. — At baseline and 6 month foll…; Change in Sense of Smell as Measured by UPSIT — At baseline and 6 month follow-up visit.; Death — Up to 12 months.; Change in Ejection Fraction (EF) — At baseline and 6 month follow-up visit.; Change in Inflammatory Markers Levels — At baseline and 6 month follow-up visit.; Change in Inflammatory Markers — At baseline and 6 month follow-up visit.; Change in Inflammatory Marker D-dimer Levels — At baseline and 6 month follow-up visit.
- Reported result
- No reusable finding-level result is available in this record.
Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.
Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.
Source supportStructured registry protocol metadata; no finding-level conclusion is generated.
Registration and recruitment status do not establish safety, efficacy, or regulatory approval.
Why this record appears here · 100% topic match
The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.
- Stem cells · 100%Title contains controlled term: stem cell. Abstract contains controlled term: stem cell. Source terminology contains: stem cell. Title supplies longevity context: aging, frailty. Study type is explicitly identified as INTERVENTIONAL.
Automated source check 100% · update recency 50%. These figures help sort records; they are not medical ratings.